Raza Ur Rehman on Fitusiran as a First-in-Class RNAi Therapy in Hemophilia A and B
Raza Ur Rehman, Bachelor of Medicine and Surgery at Shaikh Khalifa bin Zayed Al Nahyan Medical and Dental College, shared on LinkedIn:
”Publication Alert
Thrilled to share that our Open Access commentary has been published in Health science Reports (Wiley )
Rebalancing Hemostasis: Fitusiran as a First-in-Class RNAi Therapy in Hemophilia A and B
Health Science Reports | Volume 9, Issue 1
(e71702)
Raza Ur Rehman, Rida Fatima, Aymar AKILIMALI
Published: 29 December 2025
This article explores Fitusiran, a groundbreaking RNAi-based antithrombin-targeting therapy, marking a paradigm shift toward factor-independent prophylaxis in hemophilia management.
• Read here.
Honored to contribute to the evolving landscape of hemophilia therapeutics and RNA-based medicine.
Feedback and discussions are most welcome!”
Article: Rebalancing Hemostasis: Fitusiran as a First-in-Class RNAi Therapy in Hemophilia A and B
Authors: Raza Ur Rehman, Rida Fatima, Aymar Akilimali
Stay updated on all scientific advances with Hemostasis Today.
-
Jan 2, 2026, 12:53José Antonio García Erce: The National Transplant Organization Published the 2024 Report of the Global Observatory on Donation and Transplantation
-
Jan 2, 2026, 12:48Reza Shojaei: Stepping into 2026 – Your Daily Commitment Saves Lives
-
Jan 2, 2026, 09:36Shashank K R on The Use of Lumbrokinase from Eudrilus eugeniae
-
Jan 2, 2026, 09:20Rehan Khan Explores Clopidogrel
-
Jan 2, 2026, 09:06Gokhan Ozdemir on Thrombophilia in Young Ischemic Stroke
-
Jan 2, 2026, 03:52Abdul Mannan: When Gender Bias Becomes a Diagnostic Error – Inherited Bleeding Disorders are Still Being Missed
-
Jan 2, 2026, 03:51Samwel Mikaye: Thrombocytopenia in Pregnancy
-
Jan 2, 2026, 03:50Marc Carrier: Clinicians Working With Cancer Patients on DOACs. We Need Your Expertise!
-
Jan 2, 2026, 03:50Emicizumab in Infants: Not Just Cost-effective but Mandatory